Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Panel Overwhelmingly Votes For Dexcom CGM to Replace Finger Sticks

Executive Summary

The US FDA's Clinical Chemistry and Clinical Toxicology Devices Panel voted eight to two to recommend Dexcom's G5 Continuous Glucose Monitor to replace finger-stick testing in diabetic patients over the age of two. Also, a post-panel podcast chat with Dexcom's Steve Pacelli.


Related Content

Dexcom First To CGM Reimbursement Finish Line
Dexcom Glucose Test System Approved For 2-Year-Olds